Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
No Chuikyo Members Call for Formulary Incentives under Medical Fee Schedule
The Central Social Insurance Medical Council (Chuikyo) discussed the introduction of medical fees that reward hospital drug formularies at its general meeting on December 8, with no opinions raised to support the idea towards the FY2022 reimbursement reform. In December…
To read the full story
Related Article
- Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
December 20, 2021
- Payers Want Low-Generic Fee Cuts Applied to Medical Institutions Too: Chuikyo
December 9, 2021
- Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
July 21, 2021
- Japan Govt to Compile Formulary Guidelines by FY2022: Reform Timeline
December 21, 2020
- MHLW Collecting Evidence to Discuss Introduction of Medical Fee for Hospital Formularies in FY2022 Reimbursement Reform
November 18, 2020
REGULATORY
- Japan Panel Again Defers Male HPV Shots amid Cost-Effectiveness Concerns
October 9, 2026
- Takaichi Defends Off-Year Drug Price Revisions as DPP Calls for Abolition
October 9, 2026
- Japan Orders Contraindication for Adlumiz-Noxafil Combination
October 9, 2026
- Imcivree, Hibsago Get Chuikyo Nod for Home Self-Injection
October 9, 2026
- Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…